6533b7d0fe1ef96bd125ac0d

RESEARCH PRODUCT

Factors related to early castration resistance in metastatic prostate cancer. Results from the National Prostate Cancer Registry in Spain

José María Martínez-jabaloyasGrupo Español De Cáncer De PróstataF. Gómez-veigaJosé Manuel Cózar-olmoAlfredo Rodríguez-antolínMarcos Antonio Lloret-duràLorena Valls-gonzálezJorge Panach-navarreteB. Miñana-lópez

subject

Oncologymedicine.medical_specialtyUnivariate analysisMultivariate analysisbusiness.industry030232 urology & nephrologyPerineural invasionGeneral Medicinemedicine.diseaseLower risk03 medical and health sciencesProstate cancer0302 clinical medicineCastration ResistanceInternal medicineTumor stagemedicinebusinessNadir (topography)

description

Abstract Introduction The objective of the study was to determine the factors independently related with the development of castration resistance (CR) in prostate cancer (PC) in the medium term. Material and methods 155 patients diagnosed with metastatic PC with a follow-up of up to 39 months. Data taken from the National PC Registry. The evaluated variables were age, PSA, nadir PSA, Gleason, perineural invasion, TNM stages, and ADT type (intermittent / continuous). Results Mean follow-up 26,2 ± 13,4 months. 47.1% developed early CR, with mean time until onset of 12,2 ± 8,7 months. Univariate analysis: the mean PSA was correlated with CR (290 ± 905,1 ng/mL in non CR, 519,1 ± 1437,2 ng/mL in CR, p  Multivariate analysis: the independent variables associated to CR are age (HR: 0.96. 95% CI: 0.94-0.99, p = 0.01), PSA nadir (HR: 1.65. 95% CI: 1,43–1,91, p  Conclusions PSA nadir and T3-T4 tumor stage at diagnosis are associated to an increased risk of developing CR. In addition, age at diagnosis is shown as a variable that decreases risk. Therefore, an older age would be associated with lower risk probability of CR in the medium term.

https://doi.org/10.1016/j.acuroe.2019.04.007